Last $3.16 USD
Change Today -0.02 / -0.63%
Volume 62.7K
WGBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

wafergen bio-systems inc (WGBS) Key Developments

WaferGen Bio-Systems, Inc. Announces Unaudited Consolidated Earnings and Operating Results for the Third Quarter and Nine Months Ended September 30, 2014; Reaffirms Earnings Guidance for the Full Year 2014; Appoints Keith Warner as Chief Operating Officer and Michael P. Henighan as Chief Financial Officer

WaferGen Bio-systems, Inc. announced unaudited consolidated earnings and operating results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total Revenues were $1,250,201 against $389,547 a year ago. The increase total revenue is primarily due to revenue from the Apollo 324TM library prep products acquired in early 2014, which accounted for 46% of product revenue in the third quarter of 2014. Operating loss was $3,128,194 against $3,228,005 a year ago. Net loss before provision for income taxes was $2,780,535 against $10,807,802 a year ago. Net loss attributable to common stockholders was $2,780,535 against $12,246,825 a year ago. Net loss per share basic and diluted was $1.02 against $43.51 a year ago. The lower net loss was primarily due to a reduction in non-operating expenses of $7.9 million, mainly due to the absence of $7.5 million in non-cash charges related to capital restructuring in 2013. For the nine months, the company reported total Revenues were $4,389,622 against $814,282 a year ago. Operating loss was $8,931,669 against $7,788,330 a year ago. Net loss before provision for income taxes was $7,426,462 against $17,749,806 a year ago. Net loss attributable to common stockholders was $7,429,562 against $22,097,341 a year ago. Net loss per share basic and diluted was $4.87 against $180.16 a year ago. The company announced the appointment of Keith Warner as Chief Operating Officer and Michael P. Henighan as Chief Financial Officer, adding seasoned executives to senior management team. The revenue guidance for the full year is in excess of $6 million for 2014, unchanged from prior guidance.

WaferGen Bio-systems, Inc., Q3 2014 Earnings Call, Nov 07, 2014

WaferGen Bio-systems, Inc., Q3 2014 Earnings Call, Nov 07, 2014

WaferGen Bio-systems, Inc. Launches Next Generation Sequencing Sample Preparation Platform Apollo 324

WaferGen Bio-systems, Inc. announced the launch of an automated solution for Agilent's SureSelect Target Enrichment workflow on the Apollo 324 Next Generation Sequencing sample preparation system. WaferGen responded to customers' unmet needs for a cost effective and flexible automated target capture solution. The Apollo 324 protocols were designed to enable researchers to utilize Agilent's SureSelect Reagent Kits with a decreased turnaround time, thereby improving throughput with the expanded flexibility to prepare a wide range of samples per run. This solution will be of great use to clinical CLIA labs, as well as clinical research institutions. The Apollo 324 NGS Library Prep System is a compact and flexible system that enables rapid and full walk-away automation of a wide variety of Next Generation Sequencing applications. WaferGen also offers complete solutions with PrepX reagent kits that are designed specifically for ease-of-use with Apollo 324 automated protocols. PrepX reagents are color-coded and prealiquotted with the necessary volume per reaction, significantly reducing hands-on time and operator error. WaferGen continues to develop new applications for Apollo 324, including second generation whole exome solutions and plans to launch additional solutions in the first quarter of 2015.

WaferGen Bio-systems, Inc., Special/Extraordinary Shareholders Meeting, Nov 17, 2014

WaferGen Bio-systems, Inc., Special/Extraordinary Shareholders Meeting, Nov 17, 2014., at 10:00 Pacific Standard Time. Location: 7400 Paseo Padre Parkway. Agenda: To amend the WaferGen Bio-systems, Inc., 2008 stock incentive plan to increase the number of shares of the company's common stock that may be issued pursuant to awards under the plan from 314,589 shares to 1,214,589, limit the maximum number of plan shares that may be awarded to any individual in one year to 500,000, extend the plan's expiration date, and re-approve the material terms of the plan for purposes of Section 162(m) of the internal revenue Code of 1986; to approve the adjournment of the special meeting, if necessary, to solicit additional proxies to vote in favor of the foregoing proposal; and to transact such other business as may properly come before the special meeting or any adjournment or postponement thereof.

WaferGen Biosystems, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 02:30 PM

WaferGen Biosystems, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 02:30 PM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Ivan D. Trifunovich, Chairman of the Board, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WGBS:US $3.16 USD -0.02

WGBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $4.68 USD 0.00
Exiqon A/S kr6.45 DKK -0.05
NanoString Technologies Inc $13.76 USD -0.73
Pacific Biosciences of California Inc $7.50 USD +0.23
Sequenom Inc $3.60 USD -0.04
View Industry Companies
 

Industry Analysis

WGBS

Industry Average

Valuation WGBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WAFERGEN BIO-SYSTEMS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.